Dosing for Personalized Prophylaxis in Hemophilia A highly varies on the underlying Population Pharmacokinetic Models.
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic drug monitoring"
DOI: 10.1097/ftd.0000000000000983
Abstract: BACKGROUND Model-informed personalized prophylaxis with factor VIII (FVIII) replacement therapy aimed at higher trough levels is becoming indispensable for patients with severe hemophilia A. This study aimed to identify the most suitable population pharmacokinetic (PK)… read more here.
Keywords: pharmacokinetic models; population; population pharmacokinetic; model ... See more keywords